The Future of the Treatment of TNBC

Clinical Pearls

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).

• BRCA-like or basal-like breast cancer that is triple-negative is particularly aggressive. Platinums may be more effective in this space.
• Many pharmaceutical companies are not looking at PARP inhibitors in large studies because of the results of 1 negative trial.
• Many TNBCs have downregulation of BRCA proteins where inhibiting PARP may be particularly effective.
• Some studies are also looking at antibodies and antibody-directed therapies to inhibit the NOTCH pathway.